SCM
PTCT icon

Stonebridge Capital Management’s PTC Therapeutics PTCT Stock Holding History

Stonebridge Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-21,385
Closed -$150K – 137
2016
Q2 		$150K Sell
21,385
-53,325
-71% -$391K 0.07% 111
2016
Q1 		$481K Buy
74,710
+64,560
+636% +$1.12M 0.21% 82
2015
Q4 		$329K Sell
10,150
-3,635
-26% -$107K 0.14% 122
2015
Q3 		$368K Buy
13,785
+6,445
+88% +$276K 0.17% 115
2015
Q2 		$353K Buy
+7,340
New +$428K 0.14% 116

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Stonebridge Capital Management's PTCT Position: Q3 2016 in Review

Stonebridge Capital Management sold out of PTC Therapeutics (PTCT) in Q3 2016, closing a stake of 21,385 shares — an estimated $150K sold.

Stonebridge Capital Management first reported a position in PTCT in Q2 2015 and held it in 5 quarters. The position peaked at $481K in Q1 2016. 115 funds tracked by Wall St. Rank hold PTCT as of Q3 2016.

  • Stonebridge Capital Management reported no remaining PTC Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Stonebridge Capital Management sold 21,385 PTC Therapeutics shares in Q3 2016, an estimated $150K.
  • Stonebridge Capital Management first reported a position in PTC Therapeutics in Q2 2015 and held it in 5 quarters.
  • Stonebridge Capital Management's PTC Therapeutics position peaked at $481K in Q1 2016.
  • 115 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2016.

Based on Stonebridge Capital Management's 13F filing for Q3 2016, filed 17 Oct 2016.